SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Gross Profit Growth Recovery in ProgressRecovering
Percentile Rank83
5Y CAGR-62.5%
Studio
Year-over-Year Change

Year-over-year gross profit growth rate

5Y CAGR
-62.5%/yr
Long-term compound
Percentile
P83
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
202511.20%
2024-130.42%
2023-107.31%
2022-65.20%
20217.21%
20201504.82%
20190.00%